Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
08 janv. 2024 08h00 HE
|
Wave Life Sciences USA, Inc.
Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever RNA editing proof-of-mechanism in humans Selection of...
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds
07 déc. 2023 08h00 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference
17 nov. 2023 08h00 HE
|
Benitec Biopharma Inc.
HAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
09 nov. 2023 16h30 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
09 nov. 2023 07h30 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control
03 nov. 2023 12h00 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
12 oct. 2023 11h00 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is...
Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894
11 oct. 2023 07h30 HE
|
Phio Pharmaceuticals Corp.
--Preclinical data shows melanoma cells treated with PH-894 makes them more recognizable to immune cells, increasing potential for elimination --Preclinical data demonstrates the effectiveness of...
RNAi Drug Delivery Technologies and Global Market Analysis Report 2023: Historic Market Revenue from 2020 to 2022, Estimates for 2023, and CAGR Projections through to 2028
29 août 2023 07h08 HE
|
Research and Markets
Dublin, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The "RNAi Drug Delivery: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global RNAi drug delivery...
RNA Therapy Clinical Trials Market Report 2023-2030: Strategies and Collaborations Shaping the Industry
29 août 2023 04h48 HE
|
Research and Markets
Dublin, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The "RNA Therapy Clinical Trials Market Size, Share & Trends Analysis Report, 2023-2030" report has been added to ResearchAndMarkets.com's offering. ...